Torrent Pharma Q2 net profit dips 12 pc to Rs 179 crore

New Delhi: Drug firm Torrent Pharmaceuticals has reported a 12.25 per cent dip in its consolidated net profit to Rs 179 crore for the quarter ended September 2018 due to one-time impact of a product recall in the US and rupee depreciation. The company had posted a net profit of Rs 204 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a statement.

Its total revenue, however, on a consolidated basis rose to Rs 1,894 crore for the quarter under consideration as against Rs 1,417 crore for the same period a year ago.

The company’s net profit was impacted as depreciation and amortisation was higher by Rs 68 crore on account of acquired business, one time impact of product recall in US of Rs 25 crore and lower hedging gains due to rupee depreciation, Torrent Pharmaceuticals said.

The research and development spend for the second quarter this fiscal was also higher at Rs 136 crore as against Rs 107 crore in the year ago period, it added.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre